REGENERX
RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRxโs mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tฮฒ4) allowed the company to ... direct its focus on tissue protection and repair in multiple disease indications. RegeneRxโs management team is focused on moving three distinct Tฮฒ4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 60 issued patents or filed patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. In addition to Tฮฒ4, RegeneRx is developing Tฮฒ4 peptide fragments for cosmeceutical applications, separate and distinct from the pharmaceutical peptide and formulations. RegeneRx intends to pursue strategic business relationships to develop these smaller peptides for the cosmeceutical market.
REGENERX
Industry:
Biopharma Biotechnology Medical
Founded:
2002-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.regenerx.com
Total Employee:
11+
Status:
Active
Contact:
(502)569-1059
Email Addresses:
[email protected]
Total Funding:
11.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail ReCAPTCHA JsDelivr
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.regenerx.com
- Host name: 173.203.62.111
- IP address: 173.203.62.111
- Location: San Antonio United States
- Latitude: 29.3856
- Longitude: -98.5247
- Metro Code: 641
- Timezone: America/Chicago
- Postal: 78225
